Tune in for an engaging discussion around data presented at the ASH Annual Meeting 2021 on the use of late generation tyrosine kinase inhibitors in CML. Gianantonio Rosti (Meldola, Italy) explores the clinical experiences and insights of an interdisciplinary European faculty (Delphine Rea, Paris, France; Fausto Castagnetti, Bologna, Italy; and Valentin Garcia-Gutierrez, Madrid, Spain).
Leading expert in the optimization of tyrosine kinase inhibitor therapies in CML.
Tune in for an engaging discussion around data presented at the ASH Annual Meeting 2021 on second-line CAR-T cell therapy and real-world evidence in FL/DLBCL. Mats Jerkeman (Lund, Sweden) explores the clinical experiences and insights of an interdisciplinary European faculty (Marion Subklewe, Munich, Germany; Steven Le Gouill, Paris, France; and Toby Eyre, Oxford, United Kingdom).
Leading expert in the use of immunotherapies for the management of malignant lymphomas.
The content and faculty for this program have been independently developed and/or selected by Springer Healthcare. Novartis Pharmaceutical Corporation provided unconditional funding and as such had no involvement with, or influence on the content and selection of faculty. The content is not intended for use by healthcare professionals in the US. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not reflect the views of Springer Healthcare. Springer Healthcare assumes no responsibility for any injury or damage to persons or property arising out of, or related to, any use of the material or to any errors or omissions. Please consult the latest prescribing information from the manufacturer for any products mentioned in this material.